These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

469 related items for PubMed ID: 23048108

  • 1. In Medicare Part D plans, low or zero copays and other features to encourage the use of generic statins work, could save billions.
    Hoadley JF, Merrell K, Hargrave E, Summer L.
    Health Aff (Millwood); 2012 Oct; 31(10):2266-75. PubMed ID: 23048108
    [Abstract] [Full Text] [Related]

  • 2. Encouraging generic use can yield significant savings.
    Zimmerman C.
    Find Brief; 2012 Nov; 15(8):1-3. PubMed ID: 23213854
    [Abstract] [Full Text] [Related]

  • 3. Zero copayment for generic statins could save billions.
    Manag Care; 2013 Mar; 22(3):44. PubMed ID: 23610806
    [No Abstract] [Full Text] [Related]

  • 4. Impact of cost sharing on prescription drugs used by Medicare beneficiaries.
    Goedken AM, Urmie JM, Farris KB, Doucette WR.
    Res Social Adm Pharm; 2010 Jun; 6(2):100-9. PubMed ID: 20511109
    [Abstract] [Full Text] [Related]

  • 5. Patient and Payer Incentives to Use Patented Brand-Name Drugs vs Authorized Generic Drugs in Medicare Part D.
    Dusetzina SB, Sarpatwari A, Carrier MA, Hansen RA, Keating NL, Huskamp HA.
    JAMA Intern Med; 2021 Dec 01; 181(12):1605-1611. PubMed ID: 34661600
    [Abstract] [Full Text] [Related]

  • 6. Cost variability of suggested generic treatment alternatives under the Medicare Part D benefit.
    Patel RA, Walberg MP, Tong E, Tan F, Rummel AE, Woelfel JA, Carr-Lopez SM, Galal SM.
    J Manag Care Spec Pharm; 2014 Mar 01; 20(3):283-90. PubMed ID: 24564812
    [Abstract] [Full Text] [Related]

  • 7. Does the offer of free prescriptions increase generic prescribing?
    Stuart B, Hendrick F, Dougherty JS, Xu J.
    Am J Manag Care; 2017 Jun 01; 23(6):e193-e201. PubMed ID: 28817295
    [Abstract] [Full Text] [Related]

  • 8. Impact of medicare part D plan features on use of generic drugs.
    Tang Y, Gellad WF, Men A, Donohue JM.
    Med Care; 2014 Jun 01; 52(6):541-8. PubMed ID: 24824538
    [Abstract] [Full Text] [Related]

  • 9. Medicare Spending on Brand-name Combination Medications vs Their Generic Constituents.
    Sacks CA, Lee CC, Kesselheim AS, Avorn J.
    JAMA; 2018 Aug 21; 320(7):650-656. PubMed ID: 30140875
    [Abstract] [Full Text] [Related]

  • 10. Impact of final short-fill rule on Medicare Part D costs and long-term care pharmacy dispensing.
    Bazalo G, Weiss RC.
    Consult Pharm; 2012 Apr 21; 27(4):269-73. PubMed ID: 22498986
    [Abstract] [Full Text] [Related]

  • 11. Trends in Utilization and Cost of Low-Density Lipoprotein Cholesterol-Lowering Therapies Among Medicare Beneficiaries: An Analysis From the Medicare Part D Database.
    Sumarsono A, Lalani HS, Vaduganathan M, Navar AM, Fonarow GC, Das SR, Pandey A.
    JAMA Cardiol; 2021 Jan 01; 6(1):92-96. PubMed ID: 32902560
    [Abstract] [Full Text] [Related]

  • 12. Beneficiary price sensitivity in the Medicare prescription drug plan market.
    Frakt AB, Pizer SD.
    Health Econ; 2010 Jan 01; 19(1):88-100. PubMed ID: 19191252
    [Abstract] [Full Text] [Related]

  • 13. Impact of formulary restrictions on medication use and costs.
    Shen X, Stuart BC, Powers CA, Tom SE, Magder LS, Perfetto EM.
    Am J Manag Care; 2017 Aug 01; 23(8):e265-e274. PubMed ID: 29087150
    [Abstract] [Full Text] [Related]

  • 14. Association of Industry Payments to Physicians With the Prescribing of Brand-name Statins in Massachusetts.
    Yeh JS, Franklin JM, Avorn J, Landon J, Kesselheim AS.
    JAMA Intern Med; 2016 Jun 01; 176(6):763-8. PubMed ID: 27159336
    [Abstract] [Full Text] [Related]

  • 15. Brand Medications and Medicare Part D: How Eye Care Providers' Prescribing Patterns Influence Costs.
    Newman-Casey PA, Woodward MA, Niziol LM, Lee PP, De Lott LB.
    Ophthalmology; 2018 Mar 01; 125(3):332-339. PubMed ID: 28625684
    [Abstract] [Full Text] [Related]

  • 16. Medicare Part D Plans Rarely Cover Brand-Name Drugs When Generics Are Available.
    Dusetzina SB, Cubanski J, Nshuti L, True S, Hoadley J, Roberts D, Neuman T.
    Health Aff (Millwood); 2020 Aug 01; 39(8):1326-1333. PubMed ID: 32744944
    [Abstract] [Full Text] [Related]

  • 17. Relationship between generic and preferred-brand prescription copayment differentials and generic fill rate.
    Mager DE, Cox ER.
    Am J Manag Care; 2007 Jun 01; 13(6 Pt 2):347-52. PubMed ID: 17567235
    [Abstract] [Full Text] [Related]

  • 18. The effect of incentive-based formularies on prescription-drug utilization and spending.
    Huskamp HA, Deverka PA, Epstein AM, Epstein RS, McGuigan KA, Frank RG.
    N Engl J Med; 2003 Dec 04; 349(23):2224-32. PubMed ID: 14657430
    [Abstract] [Full Text] [Related]

  • 19. Potential savings from increased use of generic drugs in the elderly: what the experience of Medicaid and other insurance programs means for a Medicare drug benefit.
    Fischer MA, Avorn J.
    Pharmacoepidemiol Drug Saf; 2004 Apr 04; 13(4):207-14. PubMed ID: 15255087
    [Abstract] [Full Text] [Related]

  • 20. Drug plan design incentives among Medicare prescription drug plans.
    Huskamp HA, Keating NL, Dalton JB, Chernew ME, Newhouse JP.
    Am J Manag Care; 2014 Jul 04; 20(7):562. PubMed ID: 25295402
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.